Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KDM5A | P29375 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31522110 | 1.00 | CYP19A1 (0.49) | CYP19A1TBXAS1IDO1ALDH1A1SIGMAR1 | |
| SCHEMBL15320085 | 0.94 | HTR6 (0.46) | CYP19A1TBXAS1IDO1SIGMAR1 | |
| SCHEMBL1125363 | 0.88 | HTR6 (0.54) | IDO1PDPK1 | |
| SCHEMBL29511517 | 0.88 | HTR6 (0.54) | IDO1PDPK1 | |
| SCHEMBL14015841 | 0.88 | HTR6 (0.54) | IDO1PDPK1 | |
| SCHEMBL5477158 | 0.87 | CYP19A1 (0.55) | CYP19A1TBXAS1IDO1SIGMAR1 | |
| SCHEMBL7898127 | 0.84 | IDO1 (0.52) | CYP19A1TBXAS1IDO1SIGMAR1 | |
| SCHEMBL80413 | 0.84 | SIGMAR1 (0.56) | CYP19A1TBXAS1SIGMAR1 | |
| SCHEMBL12507093 | 0.81 | CYP19A1 (0.49) | CYP19A1TBXAS1IDO1SIGMAR1PDPK1 | |
| SCHEMBL1566770 | 0.81 | CYP19A1 (0.49) | CYP19A1TBXAS1IDO1ALDH1A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5073654-A | Catalyzing in presence of zeolite type beta | UOP (US) | 1991-12-17 | — | — | US | claimed |
| CN-110382574-A | Heterophasic propylene polymeric material and Propenes resin composition | 住友化学株式会社 | 2019-10-25 | — | — | CN | disclosed |
| CN-110098408-A | The manufacturing method of electrode composition, battery and electrode | 松下知识产权经营株式会社 | 2019-08-06 | — | — | CN | disclosed |
| US-10316035-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-06-11 | — | — | US | disclosed |
| US-10316035-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180319793-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-11-08 | — | — | US | disclosed |
| EP-2562156-B1 | COLCHICINE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, METHOD FOR PREPARING SAID DERIVATIVES, AND PHARMACEUTICAL COMPOSITION COMPRISING SAID DERIVATIVES | ASAN FOUND (KR) | 2018-11-07 | — | — | EP | disclosed |
| US-20180244671-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2018-08-30 | — | — | US | disclosed |
| CN-105073958-B | The manufacturing method of extract residue | 株式会社神户制钢所 | 2018-08-24 | — | — | CN | disclosed |
| CN-108350363-A | Can photo-alignment material composition | 罗利克技术有限公司 | 2018-07-31 | — | — | CN | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-20040242554-A1 | CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES | BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION | 2004-12-02 | — | — | US | disclosed |
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION | 2003-05-15 | — | — | US | disclosed |
| US-6465467-B1 | DISEASES RELATED TO THE 5-HT2C RECEPTOR, ESPECIALLY EATING, MEMORY, MOOD, URINARY AND ANXIETY DISORDERS, SCHIZOPHRENIA, PAIN, SEXUAL DYSFUNCTIONS | BIOVITRUM AB (SE) | 2002-10-15 | — | — | US | disclosed |
| EP-1178973-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | Pharmacia AB (SE) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000076984-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2000-12-21 | — | — | WO | disclosed |
| EP-0281283-B1 | HETEROCYCLIC COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-02-10 | — | — | EP | disclosed |
| US-5073654-A | Catalyzing in presence of zeolite type beta | UOP (US) | 1991-12-17 | — | — | US | disclosed |
| US-4910212-A | Containing 1,2,4-triazole or imidazole ring | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-03-20 | — | — | US | disclosed |
| EP-0281283-A1 | Heterocyclic compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319793-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | CYP19A1 648/4885TBXAS1 1152/4885IDO1 262/4885 |
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | HTR2C, HTR3C, HTR2A | CYP19A1 198/4885TBXAS1 903/4885IDO1 428/4885 |
| US-10316035-B2 | Triazolopyridine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | CYP19A1 1396/4885TBXAS1 172/4885IDO1 208/4885 |
| US-20040242554-A1 | CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES | HTR2C, HTR3C, HTR2A | CYP19A1 190/4885TBXAS1 933/4885IDO1 384/4885 |
| US-20180244671-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | CYP19A1 1396/4885TBXAS1 172/4885IDO1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.